Precision Therapeutics Inc. | Business Contracts

Employment Agreement dated effective November 1, 2022 by and between Raymond F. Vennare and Predictive Oncology Inc (Filed With SEC on October 20, 2022)

Securities Purchase Agreement (Second Offering) (Filed With SEC on May 18, 2022)

Engagement Letter with H.C. Wainwright & Co., dated May 9, 2022 (Filed With SEC on May 18, 2022)

Agreement and Plan of Merger dated November 24, 2021 by and among the Company, Golden Gate Acquisition, Inc., zPredicta, Inc. and Tom Kelly, as Representative (Filed With SEC on December 1, 2021)

Placement Agency Agreement (Filed With SEC on October 10, 2019)

Employment Offer Letter dated September 30, 2022 by and between Raymond F. Vennare and Predictive Oncology Inc (Filed With SEC on October 20, 2022)

Transition and Separation Agreement dated September 15, 2022 by and between J. Melville Engle and Predictive Oncology Inc (Filed With SEC on September 16, 2022)

Amended and Restated Employment Agreement, effective as of August 1, 2022, by and between Julia Kirshner and Predictive Oncology Inc (Filed With SEC on July 26, 2022)

Securities Purchase Agreement (First Offering) (Filed With SEC on May 18, 2022)

Form of Warrant Amendment Agreement (Filed With SEC on May 18, 2022)

Form of Placement Agent Warrant (Filed With SEC on May 18, 2022)

Form of Investor Warrant (Filed With SEC on May 18, 2022)

Form of Stock Option Agreement for Employees under Amended and Restated 2012 Stock Incentive Plan (Filed With SEC on March 31, 2022)

Description of Registrants Securities (Filed With SEC on March 31, 2022)

Form of Stock Option Agreement for Directors under Amended and Restated 2012 Stock Incentive Plan (Filed With SEC on March 31, 2022)

Form of Stock Option Agreement for Executive Officers under Amended and Restated 2012 Stock Incentive Plan (Filed With SEC on March 31, 2022)

Form of Securities Purchase Agreement, dated June 14, 2021, by and between Predictive Oncology Inc. and certain Purchasers (Filed With SEC on June 16, 2021)

Form of Placement Agent Warrant (Filed With SEC on June 16, 2021)

Form of Warrant (Filed With SEC on June 16, 2021)

Amendment to Engagement Letter (Filed With SEC on June 16, 2021)

2021 Long Term Incentive Plan (Filed With SEC on May 20, 2021)

Employment Agreement by and between the Company and J. Melville Engle dated effective as of March 19, 2021 (Filed With SEC on April 7, 2021)

Transition and Separation Agreement by and between the Company and Carl Schwartz dated March 19, 2021 (Filed With SEC on March 23, 2021)

Agreement and Release by and between the Company and Carl Schwartz dated March 19, 2021 (Filed With SEC on March 23, 2021)

Offer Letter by and between the Company and J. Melville Engle dated March 19, 2021 (Filed With SEC on March 23, 2021)

Common Stock Purchase Warrant issued to Oasis Capital, LLC dated March 6, 2020 (50) Exhibit 4.30 (Filed With SEC on March 15, 2021)

Registration Rights Agreement by and among the Company and the Investors dated February 18, 2021 (Filed With SEC on February 22, 2021)

Securities Purchase Agreement by and among the Company and the Investors dated February 18, 2021 (Filed With SEC on February 22, 2021)

Form of Warrant (Filed With SEC on February 22, 2021)

Form of Securities Purchase Agreement, dated February 10, 2021, by and between Predictive Oncology Inc. and certain Purchasers (Filed With SEC on February 12, 2021)

Form of Warrant (Filed With SEC on February 12, 2021)

Form of Placement Agent Warrant issued to H.C. Wainwright & Co., LLC or its designees in connection with certain financing transactions in 2020 and 2021 (Filed With SEC on January 29, 2021)

Form of Warrant (Filed With SEC on January 26, 2021)

Form of Securities Purchase Agreement, dated January 21, 2021, by and between Predictive Oncology Inc. and certain Purchasers (Filed With SEC on January 26, 2021)

Form of Warrant (Filed With SEC on January 21, 2021)

Form of Securities Purchase Agreement, dated January 19, 2021, by and between Predictive Oncology Inc. and certain Purchasers (Filed With SEC on January 21, 2021)

Form of Securities Purchase Agreement, dated January 8, 2021, by and between Predictive Oncology Inc. and certain Purchasers (Filed With SEC on January 12, 2021)

Form of Warrant (Filed With SEC on January 12, 2021)

Engagement Letter (Filed With SEC on January 12, 2021)

Form of Warrant dated April 4, 2019 issued in Exchange Offer with Holders of Securities of Helomics Holding Corporation, as amended on September 14, 2020 (Filed With SEC on November 16, 2020)

Amendment #2 to the Senior Secured Promissory Note originally issued on February 5, 2020 by and among the Company and Oasis Capital, LLC (Filed With SEC on September 30, 2020)

Amendment #3 to the Senior Secured Promissory Note originally issued on September 27, 2019 by and among the Company and Oasis Capital, LLC (Filed With SEC on September 30, 2020)

Amendment #5 to the Amended and Restated Senior Secured Promissory Note originally issued on September 28, 2018 by and among the Company and L2 Capital, LLC (Filed With SEC on September 30, 2020)

Form of Amendment to Common Stock Purchase Warrant (Filed With SEC on September 24, 2020)

Amendment #4 to the Amended and Restated Senior Secured Promissory Note originally issued on September 28, 2018 by and among the Company and L2 Capital, LLC (Filed With SEC on July 20, 2020)

Amendment #1 to the Senior Secured Promissory Note originally issued on February 5, 2020 by and among the Company and Oasis Capital, LLC (Filed With SEC on July 20, 2020)

Amendment #2 to the Senior Secured Promissory Note originally issued on September 27, 2019 by and among the Company and Oasis Capital, LLC (Filed With SEC on July 20, 2020)

Asset Purchase Agreement, dated July 1, 2020, by and among the Selling Parties and the Company (Filed With SEC on July 7, 2020)

Form of New Warrant (Filed With SEC on June 26, 2020)

Form of Warrant Exercise Agreement (Filed With SEC on June 26, 2020)

Asset Purchase Agreement, dated May 27, 2020, by and among InventaBioTech, Inc., Soluble Therapeutics, Inc., BioDtech, Inc., and Predictive Oncology Inc (Filed With SEC on June 2, 2020)

Securities Purchase Agreement, dated May 6, 2020, by and between Predictive Oncology Inc. and certain Purchasers (Filed With SEC on May 8, 2020)

Form of Warrant (Filed With SEC on May 8, 2020)

Engagement Letter (Filed With SEC on May 8, 2020)

Promissory Note dated April 20, 2020 between the Company and Park State Bank (Filed With SEC on May 1, 2020)

Exchange Agreement dated April 21, 2020 (Filed With SEC on April 22, 2020)

Description of Registrants Securities (Filed With SEC on April 1, 2020)

Amendment #1 to the Senior Secured Promissory Note originally issued on September 27, 2019 by and among the Company and Oasis Capital, LLC (Filed With SEC on March 23, 2020)

Amendment #3 to the Amended and Restated Senior Secured Promissory Note originally issued on September 28, 2018 by and among the Company and L2 Capital, LLC (Filed With SEC on March 23, 2020)

Corrected Form of Prefunded Warrant (Filed With SEC on March 23, 2020)

Securities Purchase Agreement by and among the Company and the Investors dated March 15, 2020 (Filed With SEC on March 16, 2020)

Registration Rights Agreement by and among the Company and the Investors dated March 15, 2020 (Filed With SEC on March 16, 2020)

Form of Prefunded Warrant (Filed With SEC on March 16, 2020)

Form of Series B Warrant (Filed With SEC on March 16, 2020)

Form of Series A Warrant (Filed With SEC on March 16, 2020)

Amended and Restated Letter Agreement dated March 15, 2020 by and between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on March 16, 2020)

Form of Common Stock Purchase Warrant issued to Oasis Capital, LLC under Security Purchase Agreement dated February 5, 2020 (Filed With SEC on February 7, 2020)

Securities Purchase Agreement dated February 5, 2020 by and between Predictive Oncology Inc. and Oasis Capital, LLC (Filed With SEC on February 7, 2020)

Senior Secured Promissory Note dated as f February 5, 2020 (Filed With SEC on February 7, 2020)

Security Agreement dated February 5, 2020 by and between Predictive Oncology Inc. and Oasis Capital, LLC (Filed With SEC on February 7, 2020)

Promissory Note to Carl Schwartz dated January 31, 2020 (Filed With SEC on February 4, 2020)

Exchange Agreement dated January 31, 2020 (Filed With SEC on February 4, 2020)

Promissory Note dated November 26, 2019 issued to L2 Capital, LLC (the same form was used for the Promissory Notes dated December 10, 2019 and will be used for a subsequent... (Filed With SEC on December 19, 2019)

Amendment No. 2 dated December 12, 2019 to Amended and Restated Senior Secured Promissory Note issued to L2 Capital, LLC (Filed With SEC on December 17, 2019)

Registration Rights Agreement by and between the Company and Oasis Capital, LLC dated October 24, 2019 (Filed With SEC on October 25, 2019)

Equity Purchase Agreement by and between the Company and Oasis Capital, LLC dated October 24, 2019 (Filed With SEC on October 25, 2019)

Form of Warrant (Filed With SEC on October 10, 2019)

Amendment No. 1 dated September 27, 2019 to Amended and Restated Senior Secured Promissory Note issued to L2 Capital, LLC (Filed With SEC on September 30, 2019)

Security Agreement by and between the Company and Oasis Capital, LLC dated September 27, 2019 (Filed With SEC on September 30, 2019)

Senior Secured Promissory Note issued to Oasis Capital, LLC dated September 27, 2019 (Filed With SEC on September 30, 2019)

Securities Purchase Agreement by and between the Company and Oasis Capital, LLC dated September 27, 2019 (Filed With SEC on September 30, 2019)

Common Stock Purchase Warrant issued to Oasis Capital, LLC dated September 27, 2019 (Filed With SEC on September 30, 2019)

Form of Amended and Restated Employment Agreement with Carl Schwartz (Filed With SEC on August 19, 2019)

Form of Amended and Restated Promissory Note payable to Carl Schwartz (Filed With SEC on August 19, 2019)

Form of Securities Purchase Agreement (Filed With SEC on July 11, 2019)

Promissory Note issued to Carl Schwartz dated May 30, 2019 (Filed With SEC on June 4, 2019)

Third Amended and Restated Common Stock Purchase Warrant issued to Carl Schwartz dated May 21, 2019 (Filed With SEC on May 23, 2019)

Consulting Agreement dated effective as of May 1, 2019 by and between the Company and Richard Gabriel (Filed With SEC on May 8, 2019)

Placement Agency Agreement (Filed With SEC on April 2, 2019)

Form of Unit Purchase Option (Filed With SEC on April 2, 2019)

Form of Warrant (Filed With SEC on April 2, 2019)

Amendment to Employment Agreement by and between the Issuer and Bob Myers dated August 20, 2018 (Filed With SEC on April 1, 2019)

Amended and Restated 2012 Stock Incentive Plan (Filed With SEC on March 22, 2019)

Form of Unit Purchase Option (Filed With SEC on March 1, 2019)

Form of Warrant (Filed With SEC on March 1, 2019)

Placement Agency Agreement (Filed With SEC on March 1, 2019)

Amended and Restated Common Stock Purchase Warrant issued to Carl Schwartz dated February 6, 2019 (Filed With SEC on February 12, 2019)

Amended and Restated Promissory Note issued to Peak One Opportunity Fund, LP dated February 7, 2019 (Filed With SEC on February 12, 2019)

Amended and Restated Promissory Note issued to L2 Capital, LLC dated February 7, 2019 (Filed With SEC on February 12, 2019)

Forbearance Agreement by and between Peak One Opportunity Fund, LP and the Company dated February 7, 2019 (Filed With SEC on February 12, 2019)

Forbearance Agreement by and between L2 Capital, LLC and the Company dated February 7, 2019 (Filed With SEC on February 12, 2019)

Amended and Restated Promissory Note issued to Carl Schwartz dated February 6, 2019 (Filed With SEC on February 12, 2019)

Amended and Restated Promissory Note issued to Carl Schwartz dated January 8, 2019 (Filed With SEC on January 14, 2019)

Subscription Agreement by and between Carl Schwartz and the Company dated January 8, 2019 (Filed With SEC on January 14, 2019)

Amended and Restated Common Stock Purchase Warrant issued to Carl Schwartz dated January 8, 2019 (Filed With SEC on January 14, 2019)

Precision Therapeutics Inc. (105)